LAUSR

IntroductionHeart failure (HF) is a complex clinical syndrome with diverse risk factors and etiologies, differing underlying pathophysiology, and large phenotypic heterogeneity.Recent FindingsAdvances in imaging techniques coupled with clinical trials that targeted only in those with impaired left ventricular ejection fraction (LVEF) have largely shaped the current management strategy for HF that focuses predominantly in patients with systolic HF. In contrast, there are no effective treatments for HF with preserved ejection fraction (HFpEF). Instead of this “one-size-fits-all” approach to treatment, better precision to define HF phenotypic classifications may lead to more efficient and effective HF disease management.ConclusionIntegrating variables—including clinical variables, HF biomarkers, imaging, genotypes, metabolomics, and proteomics—can identify different pathophysiologies, lead to more precise phenotypic classification, and warrant investigation in future clinical trials.